The Effect of Long-Acting Beta-2 Agonist Monotherapy and Long-Acting Anticholinergic Monotherapy to Quality-of-Life in Group B Stable COPD Patients. J Respirol Indones. 2022;42(4):277–281. doi:10.36497/jri.v42i4.370